Emmaus Life Sciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-7.5M | $-6.5M | $-3.7M | $-10.6M | $-15.9M | $1.4M | $-54.8M | $-72.6M |
| Depreciation & Amortization | $39.0K | $22.0K | $32.0K | $53.0K | $59.0K | $60.0K | $73.0K | $61.0K |
| Depreciation | $39.0K | $22.0K | $32.0K | $39.0K | $46.0K | $46.0K | $47.0K | $47.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $25.0K | $256.0K | $1.3M | $16.0K | $553.0K | $739.0K | — | $1.6M |
| Net Cash from Operating Activities | $-11.0K | $-2.3M | $-1.5M | $-5.1M | $-1.3M | $-2.5M | $-4.5M | $-5.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.0K | $12.0K | $17.0K | $26.0K | $73.0K | $15.0K | $60.0K | $94.0K |
| Business Acquisitions | — | — | — | — | — | — | $1.6M | $306.6K |
| Net Cash from Investing Activities | $2.2M | $2.5M | $-432.0K | $-2.4M | $-6.4M | $5.5M | $-1.5M | $-7.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-1.4M | $-1.4M | $2.5M | $7.2M | $7.4M | $-2.3M | $3.9M | $-5.6M |
| Net Change in Cash | $738.0K | $-1.2M | $526.0K | $-258.0K | $-208.0K | $718.0K | $-2.1M | $-18.7M |
| Free Cash Flow | $-12.0K | $-2.3M | $-1.5M | $-5.1M | $-1.3M | $-2.5M | $-4.6M | $-5.7M |